Table 1 Patient characteristics.
| Total | Adalimumab | Infliximab | p | |
|---|---|---|---|---|
| Number | 75 | 65 | 10 | – |
| Female n (%) | 61 (81.3) | 51 (78.5) | 10 (100) | NS* |
| Age (years) | 56 (14) | 57 (14) | 50 (14) | NS† |
| Disease duration (years) | 8 (4–15) | 8.5 (4–15) | 7.5 (6–24) | NS‡ |
| RF positive n (%) | 65 (86.7) | 58 (89.2) | 7 (70) | NS* |
| DAS28 baseline | 5.9 (1) | 5.9 (1.1) | 6 (1) | NS† |
| HAQ baseline | 1.6 (1.1–2.1) | 1.6 (1.1–2.3) | 1.6 (1.3–2) | NS‡ |
| Ph‐GDA baseline | 61 (16) | 60 (15) | 70 (19) | 0.06† |
| CRP baseline (g/l) | 15 (9–24) | 15 (8–22) | 27 (11–42) | 0.05‡ |
| Clinical response n (%) | 62 (82.7) | 55 (84.6) | 7 (70) | NS* |
| Remission (%) | 10 (13.3) | 8 (12.3) | 2 (20) | NS* |
*χ2 test; †t test; ‡Mann–Whitney test.
RF, rheumatoid factor; DAS28, 28 joint count disease activity score; Ph‐GDA, physician's global disease assessment; CRP, C‐reactive protein.